Neoadjuvant therapy in cutaneous melanoma with nodal metastasis before treatment: pathological response and outcomes in a real-world single tertiary referral centre cohort (2020–2025)

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

Tafinlar (dabrafenib) - Novartis

Keytruda (pembrolizumab) - Merck (MSD)

Mekinist (trametinib) - Novartis, BeOne Medicines

https://ecp2026.abstractserver.com/programme/#/scientific/details/presentations/1935

F. Garcia Dominguez1; C.M. Bravo García2; S. Rodríguez Calle1; D. Carrasco Fernández1; A.V. Castro Maldonado1; P.J. Muriel Cueto1; I. Catalina Fernández3; M.I. Moreno García1; J.M. Báez Perea1; M.E. Brizzi1

Sep 2, 2026